anonymous
Guest
anonymous
Guest
It was a bad bet made at the C level that Sotyktu would sell better than Otezla. Like it or not that was a bad bet. To prop up the stock BMY should spin off the derm division and reallocate assets to molecules that generate revenue. Sotyktu will suck BMY dry of resources. It's time to face the facts. If you are in dermatology, I'd be looking for other opportunities.